October 20, 2006 -- Gleevec, a Novartis drug, received approval for 5 additional disorders; Novartis also won permission to market Zaditor, an OTC drug for itchy eyes; Novocell detailed its process that converts stem cells into insulin-producing cells; Ivivi staged its IPO yesterday, so that 3 biomedical companies priced this week, while Asthmatix postponed and BioVex is listed as day-to-day; Dendreon reported further analysis of the positive Phase III data for Provenge; Lilly began a Phase III trial of Alimta for small-cell lung cancer; and Vical said a single injection of its DNA flu vaccine protected animals from the avian flu. The Centient Biotech 200™ rose 6 points to 3962, a gain of .16%. More details...
